ロード中...
Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma
AIMS: Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphoma (NHL). However, studies have suggested that the dose regimen currently used (i.e. 375 mg m(−2)) could be optimized. The aims of this study were to quantify the benefits of the new dose regimen for rit...
保存先:
| 主要な著者: | , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Blackwell Science Inc
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3376436/ https://ncbi.nlm.nih.gov/pubmed/21999172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2011.04125.x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|